Option chain shows key data for TScan Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for TScan Therapeutics.

TScan Therapeutics (NASDAQ:TCRX) Stock, Option Chain

THL Credit, Inc. 6.75% Notes due 2021

TScan Therapeutics

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Equities

News

Health Care

Offerings

Markets

Movers

General

TCRX

TScan Therapeutics&#39; stock rises after announcing a $30 million financing deal with Lynx1, extending its cash runway into 2027.

Why Is TScan Therapeutics Stock Gaining Today?

Penny Stocks

Small Cap

Intraday Update

Trading Ideas

ALAB

ANNX

DAVE

DNTH

IMNM

LAAC

MRNO

NOVA

OCGN

SMLP

TLRY

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.

Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday

Long Ideas

Insider Trades

Pre-Market Outlook

ATHA

The Dow Jones closed higher by around 10 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Around $10M Bet On This Real Estate Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

TScan Therapeutics Inc

Press Releases

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

Financing

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

Dividends

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

Earnings

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

FCNCA

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Anixa Biosciences

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Climb Bio

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

CervoMed

Elicio Therapeutics

Elutia

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genelux

HilleVax

IGM Biosciences

Inozyme Pharma

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Seres Therapeutics

OncoCyte

Senti Biosciences

Sutro Biopharma

Instil Bio

Tenaya Therapeutics

Vor Biopharma

Vaxart

XBiotech

Needham

Morgan Stanley

Barclays

HC Wainwright & Co.

Wedbush

Comments

TScan Therapeutics

TScan Therapeutics (TCRX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell